Expert Insights into the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia - Episode 5

Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

, ,

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Faculty Introductions
    EP. 2: Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
    EP. 3: Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
    EP. 4: Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
    Now Viewing
    EP. 5: Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease
    EP. 6: Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
    EP. 7: Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
    EP. 8: Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
    EP. 9: Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
    EP. 10: Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia
    x